GREENLAND MINES LTD Increase (Decrease) in Accrued Taxes Payable
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Accrued Taxes Payable of $362.70 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedTaxesPayable · last filed 2023-11-17
- GREENLAND MINES LTD increase (decrease) in accrued taxes payable for the quarter ending 2023-09-30 was $225.30K.
- GREENLAND MINES LTD increase (decrease) in accrued taxes payable for the quarter ending 2023-06-30 was -$23.55K.
- GREENLAND MINES LTD increase (decrease) in accrued taxes payable for the quarter ending 2023-03-31 was $160.95K.
- GREENLAND MINES LTD increase (decrease) in accrued taxes payable for the quarter ending 2022-12-31 was $163.32K.
- GREENLAND MINES LTD increase (decrease) in accrued taxes payable for fiscal 2022 was $243.07K.
| Period end | Increase (Decrease) in Accrued Taxes Payable 3 month | Increase (Decrease) in Accrued Taxes Payable 6 month | Increase (Decrease) in Accrued Taxes Payable 9 month | Increase (Decrease) in Accrued Taxes Payable 12 month |
|---|---|---|---|---|
| 2023-09-30 | $225.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $201.75K derived: sum of 2 quarters · filed 2023-11-17 | $362.70K 10-Q · filed 2023-11-17 | $526.02K derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | -$23.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $137.40K 10-Q · filed 2023-08-21 | $300.72K derived: sum of 3 quarters · filed 2023-10-18 | |
| 2023-03-31 | $160.95K 10-Q · filed 2023-05-24 | $324.26K derived: sum of 2 quarters · filed 2023-10-18 | ||
| 2022-12-31 | $163.32K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-10-18 | $243.07K 10-K/A · filed 2023-10-18 | ||
| 2022-09-30 | $79.75K 10-Q · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |